Xencor, Inc.

Ladies and gentlemen, thank you for standing by, and welcome to the fourth quarter and year-end ZenCorp conference call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. To ask a question during the session, you'll need to press star 1 on your telephone. Please be advised that today's conference is being recorded. If you require any further assistance, please press star 0. I would now like to hand the conference over to your speaker today, Charles Lyle, Head of Corporate Communications and Investor Relations.

Please go ahead, sir. Thank you, and good afternoon. Earlier today, we issued a press release, which outlines the topics we plan to discuss today. The press release is available at www.zencore.com. Today on our call, Basil Dahia, President and Chief Executive Officer, will provide a corporate overview and will review recent partnership news. Alan Yang, Chief Medical Officer, will review updates throughout our clinical portfolio, and John Cush, Chief Financial Officer, will review financial results. And then we'll open up the call for your questions, and we'll be joined by John DesJarlais, Chief Scientific Officer. Before we begin, I would like to remind you that during the course of this conference call, ZENCOR management may make forward-looking statements, including statements regarding the company's future financial and operating results, future market conditions, the plans and objectives of management for future operations, the company's partnering efforts, capital requirements, future product offerings, research and development programs, and the impacts of the COVID-19 pandemic on these topics. These forward-looking statements are not historical facts, but are rather based on our current expectations and beliefs and are based on information currently available to us. The outcome of the events described in these forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from the results anticipated by these forward-looking statements, including, but not limited to, those factors contained in the risk factors section of our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q. First, some housekeeping. We have renamed our programs that do not yet have confirmed non-proprietary names. In general, where there were five digits, we have shortened to just the final three digits. For example, XMAB20717 is now XMAB717. With that, let me pass the call over to Basil.

Thanks, Charles, and good afternoon, everyone. Zencore's approach to creating antibody and cytokine therapeutics is based on our XMAB protein engineering platform. It's built on our extensive protein engineering knowledge combined with our suite of XMAP FC domains, which we use to build novel molecular structures, improve natural protein and antibody functions, and create new mechanisms of therapeutic action. The plug-and-play portability of our XMAP FC domains and the speed of our protein engineering capabilities enable us to rapidly explore different targets and biologies so we can select the most promising programs to take forward. We're focusing our R&D on the expansion and use of our XMAB bispecific platform to create antibodies that bind to two or more different antigens simultaneously, and also to engineer cytokines with structures optimized for particular therapeutic use. We're currently running six phase one studies evaluating such XMAB bispecific antibodies. This way we're taking multiple simultaneous shots on goal in the clinic, and the proof of concept data we generate will guide which programs we independently advance, which we partner, and which we will terminate. Last quarter, we provided program updates for our Promodimab bispecific antibody program targeting CD20 and CD3, including plans for a potentially registrational Phase II trial we expect to start later this year. We presented interim Phase I data for XMAB717, our PD1 by CTLA4 bispecific antibody, which showed activity in multiple advanced solid tumors, including prostate cancer. And we announced that we are starting a multi-arm prostate cancer trial this year. We also presented updated data for vibocodamab, a CD123 by CD3 bispecific antibody in AML, where we identified a marker for patients more likely to respond to therapy, lower baseline leukemic disease burden. Now shifting to the preclinical front, we expect to begin the Phase I clinical trial early this year for XMAB564, our wholly owned IL-2 FC fusion engineered to selectively activate regulatory T cells for the treatment of autoimmune disease. It will be our second cytokine in the clinic and will join XMAB306, our engineered IL-15 for oncology, which is partnered with Genentech. Following behind that, we expect to follow an IND for XMAB819, our ENPP3 by CD3 bispecific for renal cell cancer later this year. And we are beginning development of our first CD28 bispecific, a B7H3 targeting molecule for potentially broad solid tumor use, including in prostate cancer. Now, our broad XMAB platform also drives our partnering strategy, which provides revenue streams, but also the opportunity to expand our clinical development scale and combination therapy options. For example, our Genentech partnership for XMAB306, which initiated dose escalation in combination with the tezolizumab, Genentech's anti-PD-L1 antibody, last quarter after starting monotherapy escalation last March. And our recently started CD28 prostate cancer discovery collaboration with Janssen against an undisclosed tumor target also gives us access to their industry-leading prostate cancer portfolio for clinical combinations with our agents. Now, before we move on to our clinical portfolio today, I want to state that we did not experience significant COVID-19 disruptions to operations during the last quarter. We'll continue to update you on impacts from COVID-19 if and when they emerge. Now, with that, I'll let Alan Yang, our Chief Medical Officer, review updates to our clinical portfolio. Alan?